# TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis

> **NCT06726577** · PHASE1,PHASE2 · RECRUITING · sponsor: **Talengen Institute of Life Sciences, Shenzhen, P.R. China.** · enrollment: 60 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** TP04HN106
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT06726577
- **Lead sponsor:** Talengen Institute of Life Sciences, Shenzhen, P.R. China.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-10
- **Primary completion:** 2027-01
- **Final completion:** 2027-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06726577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06726577, "TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06726577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*